Brief: Panbela Announces First Patient Enrolled In South Korea For Aspire Trial Studying Ivospemin In Combination With Gemcitabine and NAB-Paclitaxel In Patients With Metastatic Pancreatic Ductal Adenocarcinoma
07/03/2023 13:22
March 7 (Reuters) - Panbela Therapeutics Inc PBLA.O :
* PANBELA ANNOUNCES FIRST PATIENT ENROLLED IN SOUTH KOREA
FOR
ASPIRE TRIAL STUDYING IVOSPEMIN (SBP-101) IN COMBINATION WITH
GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH METASTATIC
PANCREATIC DUCTAL ADENOCARCINOMA
* PANBELA THERAPEUTICS INC - TARGETING INTERIM ANALYSIS IN
EARLY
2024
Source text for Eikon: ID:nGNX3M2Ck3
Further company coverage: PBLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants